BiotechTube

Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K Antagonist

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

Dec 1, 2004 → Dec 1, 2005

NCT ID
NCT00395772

About Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K Antagonist

Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K Antagonist is a phase 2 stage product being developed by Johnson & Johnson for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00395772. Target conditions include Venous Thromboembolism.

What happened to similar drugs?

6 of 20 similar drugs in Venous Thromboembolism were approved

Approved (6) Terminated (2) Active (13)
✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved
✅Apixaban + Standard of CarePfizerApproved
✅ApixabanBristol Myers SquibbApproved
✅enoxaparin sodiumSanofiApproved
✅enoxaparinSanofiApproved
✅Long DOAC + Short DOACBayerApproved
🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00395772Phase 2Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26
dalteparin injectionEisaiPhase 3
32
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
29